Agreed!! So good to see you in person Dr. Cathy Eng ! We miss you! Also you definitely win best outfit ASCO #ASCO22 #endcancer

Kids loving it!! 2 home runs and counting! Houston Astros let’s go!!

Happy to be still for a change and just enjoy this little new human

Very exciting preliminary data and so glad we had the privilege of being able to collaborate with @gritstonebio & offer this vaccine based approach to our CRC patients MD Anderson Cancer Center! Excited to participate in the frontline metastatic MSS CRC trial 🎯💉🙌🏽🤞🏽#endcancer

Our recent review on managing anal squamous cell carcinoma highlighting 🔑 clinical trials. Hope you find it helpful! 👉🏼 Metastatic or Locally Recurrent Anal Squamous Cell Carcinoma (SCAC): Current Clinical Trial Landscape and Novel Approaches ncbi.nlm.nih.gov/pmc/articles/P…

Fun to collaborate with Matt Dankner & April Rose on our shared interest in nonV600 malignancies. Unfortunately, more work to be done! nonV600 BRAF mCRC continues to be an outlier (we’ve seen this story before! 😉) in terms of response to targeted therapies, especially class 2.

Spent the last 4 weeks with a serious shift towards LIFE in the work-life balance scale⚖️! Taking paternity leave is not as conventional as it should be in the US, especially for an oncologist. Why is that friends? Best decision of my life. Happy one month birthday Lily Hope! ⚓️

Here’s to 11 years married to someone I don’t deserve! ❤️🥂👨‍👩‍👧‍👦 ☀️

Zoning at all the noise and remembering what the season is all about! Thankful for grace and especially Lily’s first Christmas! 🎄

great to see MD Anderson Cancer Center Texas Medical Center Houston Mayor's Office come together to raise awareness for colorectal cancer in #Htown and highlight our young onset CRC center! awesome job Allison Rosen, MS Nancy You Scott Kopetz George J Chang #getscreened! #goblueforCRC #ColorectalCancerAwarenessMonth

just a nice low key easter weekend with these two 😌 (if your a parent you know i’m lying!). 💗💙✝️

happy to present our #CRC TIP AACR 🎯 MDSCs in a both refractory RAS mt & MRD positive setting. Not an easy nut to crack, but it’s a start! thankful for the collaboration with MD Anderson Cancer Center scientists & investigators Dr. Ron DePinho Michael overman Scott Kopetz Van Morris, MD #AACR23

Thankful for the opportunity to increase awareness about the rising incidence of #coloncancer under the age of 50. The 2 most important things to remember here: ☝🏽If you are 45 years old- you are DUE (or OVERDUE) for a screening colonoscopy! ✌🏽LISTEN to to your body!

🚨 Rapid oral 🌍 our global Ph2 BOT/BAL in refractory MSS mCRC w/NLM presented by Dr. Marwan G. Fakih 🚨 BOT 75 + BAL ➡️ 19% ORR, 55% DCR, ✅ primary endpoint met. 0 responses w/SOC. BOT 75 combo selected for upcoming Ph 3 trials #GI25 #activateTcells #sitematters meetings.asco.org/abstracts-pres…

✅ BOT/BAL IST data in the neoadjuvant colon setting @#GI25 ! 🚨mPR & pCR rates acheived and confirmed now in 2 independent trials pave the way for next generation clinical trial designs for our pts. let’s change the course of CRC together👏🏽👏🏽GONO Foundation Manish A. Shah ASCO

Exciting momentum for BOT/BAL ESMO - Eur. Oncology: durable immune activation ➡️ survival benefit across difficult to treat tumors including MSS CRC -lnkd.in/eSDFvKfb Now, phase 3 BATTMAN begins! BOT/BAL in refractory MSS mCRC Jonathan Loree Agenus CCTG OncoAlert